Drug intelligence / Profile preview

ODA-611

Development stage: Preclinical
Lead developer: Ocean Biomedical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ODA-611 is a monoclonal antibody targeting PfGARP, the Plasmodium falciparum glutamic-acid-rich protein, developed for the treatment of malaria, specifically infection with P. falciparum. The mechanism of action is inhibition of PfGARP, which induces programmed cell death in the malaria parasite, contributing to decreased severity of infection. The drug is in preclinical development and was originally developed by Rhode Island Hospital, with current development driven by Ocean Biomedical Holdings[1][4][10].

Other names: Anti-PfGARP mAb

Targets

GLURP (Plasmodium falciparum glutamate-rich protein)

Beyond the preview

Go deeper on ODA-611.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODA-611.

Explore the full profile